Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep 18;69(9):e20230563.
doi: 10.1590/1806-9282.20230563. eCollection 2023.

Role of increased plasminogen activator inhibitor-1 and vitronectin in gestational diabetes mellitus

Levent Ozgen  1 , Gulten Ozgen  2 , Burcu Dincgez  2 , Feyza Bayram  2
Affiliations

Role of increased plasminogen activator inhibitor-1 and vitronectin in gestational diabetes mellitus

Levent Ozgen et al. Rev Assoc Med Bras (1992). .

Abstract

Objective: The aim of this study was to analyze the second-trimester levels of vitronectin and plasminogen activator inhibitor-1 in gestational diabetes mellitus.

Methods: This study was conducted between September 2020 and December 2020 at the University of Health Sciences, Bursa Yuksek Ihtisas Research and Training Hospital, Department of Obstetrics and Gynecology. A total of 30 pregnant women with gestational diabetes mellitus and 60 healthy controls between 24 and 27/6 weeks of gestation were included. The inclusion criteria were as follows: being between 18 and 45 years old and 24-27/6 gestational weeks, having singleton pregnancy, diagnosed with gestational diabetes mellitus by using a two-step challenge test. The exclusion criteria of this study were as follows: chronic inflammatory or infectious disease, fasting blood glucose>126 mg/dL, intolerance to glucose tolerance testing, abnormal liver or kidney function tests, as well as pregnancy with pre-gestational diabetes history of adverse perinatal outcomes. Serum vitronectin and plasminogen activator inhibitor-1 levels were measured using the enzyme-linked immunosorbent assay method.

Results: Vitronectin and plasminogen activator inhibitor-1 levels were higher in the gestational diabetes mellitus group compared with controls [91.85 (23.08) vs. 80.10 (39.18) ng/mL, for vitronectin and 6.50 (1.05) vs. 4.35(1.0) ng/mL, for plasminogen activator inhibitor-1 (for both p<0.001)]. vitronectin >84.7 ng/mL was found to predict gestational diabetes mellitus with a sensitivity of 70% and specificity of 63.3%. Moreover, vitronectin had a significant positive correlation with fasting blood glucose (r=0.476, p<0.001), postprandial blood glucose (r=0.489, p<0.001), HbA1c (r=0.713, p<0.001), and plasminogen activator inhibitor-1 (r=0.586, p<0.001).

Conclusion: This study revealed that second-trimester vitronectin and plasminogen activator inhibitor-1 are increased in gestational diabetes mellitus and vitronectin could be a candidate for the prediction of gestational diabetes mellitus.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: the authors declare there is no conflicts of interest.

Figures

Figure 1
Figure 1. Flowchart showing selection of gestational diabetes mellitus and non-gestational diabetes mellitus cohorts.
Figure 2
Figure 2. Receiver operating curve for the predictive value of vitronectin to diagnose gestational diabetes mellitus.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. American Diabetes Association 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2019. Diabetes Care. 2019;42(1):13–28. doi: 10.2337/dc19-S002. - DOI - PubMed
    1. Abell SK, Courten B, Boyle JA, Teede HJ. Inflammatory and other biomarkers: role in pathophysiology and prediction of gestational diabetes mellitus. Int J Mol Sci. 2015;16(6):13442–73. doi: 10.3390/ijms160613442. - DOI - PMC - PubMed
    1. Farrar D, Duley L, Dowswell T, Lawlor DA. Different strategies for diagnosing gestational diabetes to improve maternal and infant health. Cochrane Database Syst Rev. 2017;8(8):CD007122. doi: 10.1002/14651858.CD007122.pub4. - DOI - PMC - PubMed
    1. Harreiter J, Dovjak G, Kautzky-Willer A. Gestational diabetes mellitus and cardiovascular risk after pregnancy. Women's Health. 2014;10(1):91–108. doi: 10.2217/whe.13.69. - DOI - PubMed
    1. Sudasinghe BH, Wijeyaratne CN, Ginige PS. Long and short-term outcomes of gestational diabetes mellitus (GDM) among South Asian women - a community-based study. Diabetes Res Clin Pract. 2018;145:93–101. doi: 10.1016/j.diabres.2018.04.013. - DOI - PubMed